{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-109802","form_type":"8-K","ticker":"QNRX","cik":"0001671502","company_name":"Quoin Pharmaceuticals, Ltd.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.105020+00:00","generated_at":"2026-05-16T21:16:57.560042+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Quoin achieves 4% and 5% rapamycin loadings in topical and patch; clinical testing planned H1 2026","bullets":["Rapamycin loading 4% w/w in proprietary topical formulation; 5% w/w in dermal patch system.","Clinical trial and stability batch manufacture to start Q4 2025; clinical testing in H1 2026.","Initial targets: Microcystic Lymphatic Malformations and Venous Malformations (no FDA-approved treatments).","CEO notes capital raise completed to fund Netherton Syndrome pivotal studies and advance rapamycin programs.","Milestone complements ongoing late-stage Netherton Syndrome and Peeling Skin Syndrome development."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-109802","json":"https://secwatch.observer/filing/0001104659-25-109802.json","markdown":"https://secwatch.observer/filing/0001104659-25-109802.md","text":"https://secwatch.observer/filing/0001104659-25-109802.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925109802/0001104659-25-109802-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671502/000110465925109802/tm2530990d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:16:57.560042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}